Literature DB >> 19565251

Epidural abscess associated with pyogenic spondylodiscitis of the lumbar spine; evaluation of a new MRI staging classification and imaging findings as indicators of surgical management: a retrospective study of 37 patients.

Kenzo Uchida1, Hideaki Nakajima, Takafumi Yayama, Ryuichiro Sato, Shigeru Kobayashi, Ke-Bing Chen, Erisa S Mwaka, Hisatoshi Baba.   

Abstract

INTRODUCTION: The aim of this study was to review the patients with lumbar epidural abscess in terms of neurological morbidity, therapeutic outcome, and prognosis, while assessing the usefulness of a new MRI staging classification and specific imaging findings as indicators for surgical management.
MATERIALS AND METHODS: We reviewed 37 patients who sustained epidural abscess associated with pyogenic spondylodiscitis of the lumbar spine. Ten patients were treated conservatively, while 27 required urgent or elective surgical drainage. We studied patients with respect to symptomatology, Frankel-American Spinal Injury Association (ASIA) scale evaluation and a new proposed system of MRI staging of pyogenic spondylodiscitis (stages I–V).
RESULTS: Of the 37 patients with stage IV and V MRI lesions, 13 (35%) had septicemia and 8 (22%) presented with Frankel-ASIA scale C-D neurological status. All cases with ringlike enhancement on gadolinium-enhanced MRI in the epidural abscess lesions were treated surgically. Progression of local kyphosis and loss of intervertebral disk height were significantly prevented in the surgical group (P < 0.05). Improvements of neurological status and laboratory data were better in the surgical group than the conservative group (P < 0.05), with significantly short hospital stay (P < 0.05). DISCUSSION: Epidural abscess associated with pyogenic spondylodiscitis presents with various neurological symptoms. In addition to assessment of progression by clinical symptomatology, modified neurological Frankel-ASIA scaling and the currently proposed MRI staging regimen may help to consider the timing of surgical intervention. In the acute, subacute or acute-on-chronic phase and the ringlike enhancement pattern of epidural abscess on gadolinium-enhanced MRI may be an indicator for surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19565251     DOI: 10.1007/s00402-009-0928-3

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  6 in total

1.  Treatment of a Staphylococcus lugdunensis cervical epidural abscess.

Authors:  Thomas Noh; Thomas Marcus Zervos; Anne Chen; Mokbel Chedid
Journal:  BMJ Case Rep       Date:  2019-03-20

2.  Pyogenic and non-pyogenic spinal infections: emphasis on diffusion-weighted imaging for the detection of abscesses and pus collections.

Authors:  T Moritani; J Kim; A A Capizzano; P Kirby; J Kademian; Y Sato
Journal:  Br J Radiol       Date:  2014-07-07       Impact factor: 3.039

3.  Lumbar Epidural Abscesses: A Systematic Review.

Authors:  Charles N de Leeuw; Patrick R Fann; Joseph E Tanenbaum; Avery L Buchholz; Brett A Freedman; Michael P Steinmetz; Thomas E Mroz
Journal:  Global Spine J       Date:  2018-12-13

4.  Predictors of conservative treatment for pyogenic spondylitis.

Authors:  Fumitaka Kugimiya; Shigeyuki Muraki; Daisuke Nagakura; Hidemasa Umekoji; Hiromi Oda; Keisuke Takahashi
Journal:  Spine Surg Relat Res       Date:  2017-12-20

5.  Spinal Epidural Abscess: A Review of Presentation, Management, and Medicolegal Implications.

Authors:  Zachary Tuvya Sharfman; Yaroslav Gelfand; Pryiam Shah; Ari Jacob Holtzman; Joseph Roy Mendelis; Merritt Drew Kinon; Jonathan David Krystal; Allan Brook; Reza Yassari; David Claude Kramer
Journal:  Asian Spine J       Date:  2020-07-29

6.  Is There an Association Between Magnetic Resonance Imaging and Neurological Signs in Patients With Vertebral Osteomyelitis?: A Retrospective Observational Study on 121 Patients.

Authors:  Géraldine Bart; Hervé Redon; David Boutoille; Olivier Hamel; Lucie Planche; Yves Maugars; Benoit Le Goff
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.